Inhaled nitric oxide does not improve outcome in pediatric patients with acute hypoxemic resperatory failure following bone marrow transplantation

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Introduction; Pediatric patients who undergo bone marrow transplantation (BMT) and develop acute hypoxemic respiratory failure (AHRF) have a mortality rate as high as 0.88.1 Since 1995, BMT patients with AHRF have received inhaled nitric oxide (iNO) in an attempt to improve survival. Methods; A prospective, non-randomized, unblinded trial in which mechanically ventilated patients with AHRF were enrolled if the oxygenation index (OI) became ≥ 15 (OI = 100 × FiO2 × mean airway pressure/PaO2). A dose-response trial with sequential dosages of 5, 20, 40, 60, & 80 ppm iNO was followed by iNO administered at the maximal therapeutic dose. A clinical response (CR) was defined as a 20% decrease in OI from the pre-iNO baseline. Mortality was the primary outcome measure with CR as a secondary variable. Using 0.88 as the historical mortality1 and 0.50 as a goal for significant improvement, a N of 15 provides a power of > 0.80 with a = 0.05 for detecting a difference. Results: Between 1995 and 1999, 15 patients (age 13 ± 3 yrs)(mean ± 95% CI), 60 ± 28 days post-BMT with an OI = 36 ± 9 and PaOa/FiO2 = 97 ± 18 received iNO. Hematologic malignancy was the primary diagnosis in 13/15 with 14/15 allogeneic and 1 autologous BMT. Preparative regimens consisted of total body irradiation in 12/15, cyclophosphamide in 13 and thiotepa in 7. A response to iNO was demonstrated in 11/15 patients (73%). Inhaled NO was administered for 12 ± 8 days at a maximum sustained dose of 42 ± 9 ppm. Repeated measures ANOVA with Dunnett's post hoc test showed a decrease in OI compared with baseline at 20, 40, 60 and 80 ppm of iNO. The mortality rate was 1.0 with 14/15 receiving iNO when they expired. Conclusions: Despite 73% of subjects showing a clinical response to iNO, there was no decrease in mortality compared with historical controls. The absence of a clear survival advantage indicates that investigation of iNO therapy in this population by large multicenter, randomized trials may not be helpful.

Original languageEnglish (US)
Pages (from-to)A112
JournalCritical care medicine
Volume27
Issue number12 SUPPL.
DOIs
StatePublished - Jan 1 1999

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Fingerprint Dive into the research topics of 'Inhaled nitric oxide does not improve outcome in pediatric patients with acute hypoxemic resperatory failure following bone marrow transplantation'. Together they form a unique fingerprint.

  • Cite this